Abstract
The ZOMAXX I trial tested the noninferiority of a zotarolimus-eluting coronary stent (ZoMaxx(™) ) when compared with a paclitaxel-eluting coronary stent (Taxus(™) Express(2™) ) in a randomized trial of percutaneous intervention for de novo coronary artery stenosis. Angiographic analysis at the primary endpoint of 9 months has been reported previously. The purpose of this follow-on analysis was to describe the clinical results of the ZoMaxx and Taxus cohorts of the ZOMAXX I trial after 5 years.
| Original language | English |
|---|---|
| Journal | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions |
| Volume | 82 |
| Issue number | 7 |
| Pages (from-to) | 1039-47 |
| Number of pages | 9 |
| ISSN | 1522-1946 |
| DOIs | |
| Publication status | Published - 1 Dec 2013 |
Fingerprint
Dive into the research topics of 'A randomized, controlled, multicenter trial to evaluate the safety and efficacy of Zotarolimus- vs. Paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries: five-year results from the ZOMAXX I trial'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS